GRDN GUARDIAN PHARMACY SVCS INC revenue, earnings and financials
For the quarter ended June 30, 2026, GUARDIAN PHARMACY SVCS INC reported revenue of $352M (up 2.2% from a year earlier), net income of $21.9M and diluted EPS of n/a; over the last four quarters revenue was $1.46B and net income $65.9M; for the fiscal year ended December 2025 revenue was $1.45B, up 17.9% on the year before.
GRDN annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $1.45B, gross profit $293M, operating income $72.7M, net income $49.2M (margin 3.4%), EPS n/a
- Fiscal year ended Dec 2024: revenue $1.23B, gross profit $244M, operating income −$62.9M, net income −$110M (margin -9.0%), EPS n/a
GRDN quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $352M (up 2.2% year over year), net income $21.9M, EPS n/a
- Quarter ended Mar 31, 2026: revenue $337M (up 2.2% year over year), net income $13.3M, EPS n/a
- Quarter ended Dec 31, 2025 (from the annual report): revenue $398M (up 17.4% year over year), net income $20.9M, EPS n/a
- Quarter ended Sep 30, 2025: revenue $377M (up 20.0% year over year), net income $9.82M, EPS n/a
- Quarter ended Jun 30, 2025: revenue $344M (up 14.8% year over year), net income $9.03M, EPS n/a
- Quarter ended Mar 31, 2025: revenue $329M (up 19.6% year over year), net income $9.45M, EPS n/a
- Quarter ended Dec 31, 2024 (from the annual report): revenue $339M, net income $4.85M, EPS n/a
- Quarter ended Sep 30, 2024: revenue $314M (up 19.7% year over year), net income −$122M, EPS n/a
- Quarter ended Jun 30, 2024: revenue $300M, net income $0, EPS n/a
- Quarter ended Mar 31, 2024: revenue $275M, net income $7.10M, EPS n/a
- Quarter ended Sep 30, 2023: revenue $263M, net income −$7.00M, EPS n/a
GRDN cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow $100M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow $58.0M, share buybacks n/a
GRDN balance sheet
- Jun 30, 2026: cash $89.8M, total assets $444M, total liabilities $186M, shareholders' equity n/a
- Mar 31, 2026: cash $64.9M, total assets $427M, total liabilities $195M, shareholders' equity n/a
- Dec 31, 2025: cash $65.6M, total assets $413M, total liabilities $195M, shareholders' equity n/a
- Sep 30, 2025: cash $36.5M, total assets $390M, total liabilities $195M, shareholders' equity n/a
- Jun 30, 2025: cash $18.8M, total assets $356M, total liabilities $177M, shareholders' equity n/a
- Mar 31, 2025: cash $14.0M, total assets $334M, total liabilities $171M, shareholders' equity n/a
- Dec 31, 2024: cash $4.66M, total assets $321M, total liabilities $171M, shareholders' equity n/a
- Sep 30, 2024: cash $37.2M, total assets $348M, total liabilities $214M, shareholders' equity n/a, long-term debt $28.7M
What is GRDN's revenue?
GUARDIAN PHARMACY SVCS INC reported $1.46B of revenue over its last four quarters, through June 30, 2026.
Is GRDN profitable?
Yes. GUARDIAN PHARMACY SVCS INC earned $65.9M over the last four quarters.